Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Study of the Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough

Next Previous
Trial Profile

An Open Label Study of the Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ifenprodil (Primary)
  • Indications Cough; Idiopathic pulmonary fibrosis
  • Focus Proof of concept; Registrational; Therapeutic Use
  • Sponsors Algernon Pharmaceuticals

Most Recent Events

  • 22 Nov 2023 According to an Algernon Pharmaceuticals media release, on January 14, 2022, company received positive feedback from the U.S. Food and Drug Administration at its pre-Investigational New Drug (pre-IND) meeting for its investigation of Ifenprodil solely for the treatment of chronic cough.
  • 22 Nov 2023 Results presented in an Algernon Pharmaceuticals media release.
  • 01 Sep 2022 According to an Algernon Pharmaceuticals media release, full data results from this study be discussed at the 9th American Cough Conference in Reston, Virginia in June 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top